REPROSKIN™: A New Standard in Human-Relevant Skin Research
Discover REPROSKIN™, a revolutionary 3D human skin model that enhances drug discovery and dermatological research with biologically relevant insights and adaptability.
09 November 2026
Beyond Anti-TNF: Advances in Targeted Therapies for Crohn’s Disease and Ulcerative Colitis
Explore advances in targeted therapies for Crohn's disease and ulcerative colitis, focusing on IL-23 and TL1A inhibitors, and the role of precision medicine.
29 October 2026
REPROCELL Advances iPSC Innovation with MSCRF Support
REPROCELL has been awarded the Crystal Award for Innovation by MSCRF, highlighting its advancements in iPSC technology and contributions to regenerative medicine.
12 October 2026
Peripheral Blood Mononuclear Cells as Translational Tools in Drug Development
Explore the crucial role of Peripheral Blood Mononuclear Cells in drug development, enhancing immunotherapy, biomarker discovery, and personalized medicine.
01 October 2026
More Than Half a Century of Drug Development Attrition: Why Better Human-Relevant Models Are Needed
Explore the urgent need for human-relevant models in drug development to reduce high clinical attrition rates and improve patient outcomes.
03 September 2026